Valerie Ugo

Angers, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis.

Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis.

Journal: Leukemia
Published: May 21, 2026

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Journal: HemaSphere
Published: April 27, 2026

CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms.

CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms.

Journal: Annals of hematology
Published: September 10, 2025

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Journal: Leukemia
Published: August 20, 2025

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Journal: Leukemia
Published: August 20, 2025

A molecular signature predicts hematologic evolution in polycythemia vera patients.

A molecular signature predicts hematologic evolution in polycythemia vera patients.

Journal: Leukemia
Published: April 03, 2025

Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia.

Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia.

Journal: Blood advances
Published: September 11, 2024

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.

Journal: Blood advances
Published: July 29, 2024

Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis.

Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis.

Journal: American journal of hematology
Published: March 09, 2024

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.

Journal: American journal of hematology
Published: November 10, 2023

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.

Journal: Leukemia
Published: September 05, 2023

Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.

Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.

Journal: American journal of hematology
Published: January 10, 2023
Showing 1-12 of 63

Last Updated: 09/26/2026